Transcatheter Arterial Embolization Using Nexsphere-F for Chronic Shoulder Pain Refractory to Con… (NCT07336849) | Clinical Trial Compass
RecruitingNot Applicable
Transcatheter Arterial Embolization Using Nexsphere-F for Chronic Shoulder Pain Refractory to Conservative Treatment
South Korea44 participantsStarted 2025-09-18
Plain-language summary
Evaluation of the efficacy and safety of transcatheter arterial embolization using 'Nexsphere-F' for pain relief in patients with adhesive capsulitis of the shoulder joint that does not respond to conservative treatment.
This study aims to investigate the efficacy and safety of transcatheter arterial embolization using embolic agents in patients with adhesive capsulitis of the shoulder joint. This is a single-center, prospective, open-label, randomized clinical trial.
Who can participate
Age range19 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients who have voluntarily signed a written informed consent form after receiving an explanation of the purpose, methods, and potential effects of the clinical trial
* Patients aged between 19 and 85 years
* Patients with pain persisting for more than 3 months in the affected area and with a history of receiving physical therapy, analgesics/anti-inflammatory medications, or local injection treatments
* Patients with a measured shoulder joint range of motion (ROM) of less than 90 degrees ⑤ Patients who agree not to receive any conservative treatment other than those permitted in this clinical trial (physical therapy, medication \[NSAIDs, opioid analgesics, acetaminophen\], intra-articular injections such as hyaluronic acid)
* Patients who are willing to comply with the treatment and procedures of the clinical trial and participate in all follow-up evaluations through hospital visits or telephone surveys
Exclusion Criteria:
* Patients with a history of surgery on the shoulder joint targeted for the clinical trial prior to screening
* Patients suspected of having a full-thickness rotator cuff tear
* Patients with bleeding disorders or coagulopathies (e.g., idiopathic thrombocytopenic purpura, hemophilia, disseminated intravascular coagulation)
* Patients with advanced atherosclerosis or vasospasm in the arm vessels, or those expected to have such conditions
* Patients with a known hypersensitivity to gel…
What they're measuring
1
Visual Analog Scale (VAS) score
Timeframe: Baseline and 6 months after the procedure
Trial details
NCT IDNCT07336849
SponsorChung-Ang University Hosptial, Chung-Ang University College of Medicine